Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2021-09-02 M&A Activity
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Uttalande från styrelsen för Swedish Orphan Biovitrum AB med anledning av Advents och GIC:s offentliga kontanterbjudande
M&A Activity Classification · 99% confidence The document is a formal statement from the Board of Directors of Swedish Orphan Biovitrum AB regarding a public cash offer (takeover bid) made by Agnafit Bidco (backed by Advent and GIC). The text explicitly mentions compliance with Nasdaq Stockholm's Takeover Rules ('Takeoverreglerna') and details the offer price, premium, acceptance period, and the Board's unanimous recommendation to shareholders to accept the offer. This type of document, which details a takeover proposal and the board's response/recommendation, falls under the category of M&A Activity (Takeover/Merger Activity).
2021-09-02 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the second quarter of 2021. It contains comprehensive financial statements, management commentary, and performance analysis for the specified period. It is not an announcement of a report, but the report itself, containing substantive financial data and tables. Q2 2021
2021-07-21 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Q2 2021 report' for Sobi, containing comprehensive financial statements, management commentary, and performance analysis for the second quarter and the first half of the year. It provides detailed financial tables (revenue, EBITA, cash flow, etc.) and is clearly a substantive financial report rather than a brief announcement or a certification. Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q2 2021
2021-07-21 English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement dated July 20, 2021, detailing the Board of Directors' decision to utilize a repurchase authorization granted at the Annual General Meeting (AGM) on May 4, 2021. Specifically, it concerns the repurchase of C-shares issued under an incentive program and the subsequent conversion of these shares into common stock. This action directly relates to the company managing its own shares, which falls under the definition of 'Transaction in Own Shares' (POS). It is not a general capital change (SHA) but a specific buyback/repurchase action.
2021-07-20 Swedish
The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme
Transaction in Own Shares Classification · 98% confidence The document is a press release dated July 20, 2021, announcing that the Board of Directors is exercising an authorization to repurchase its own shares (Class C shares) to secure commitments under an incentive program. The key action described is the 'repurchase of shares' and the subsequent conversion of these shares to common shares. This directly aligns with the definition of 'Transaction in Own Shares' (Code: POS), which covers company buybacks or share repurchases.
2021-07-20 English
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Earnings Release Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and reports on "Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH." It details key efficacy and safety data points from a clinical trial and concludes with contact information and a statement about information being made public pursuant to the EU Market Abuse Regulation. This structure strongly indicates an initial announcement of financial/operational results, which aligns best with the Earnings Release (ER) definition, even though the results are clinical rather than purely financial performance metrics. It is not a full Annual Report (10-K), an Interim Report (IR), or a transcript (CT). Since it is the initial release of key results, ER is the most appropriate classification. FY 2021
2021-05-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.